NBIX (Neurocrine Biosciences Inc)
Insider Trading Activity
Every open-market purchase and sale reported by NBIX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-15 | MATT ABERNETHY | Chief Financial Officer | MIXED | — | — |
| 2026-09-15 | Darin Lippoldt | Chief Legal Officer | MIXED | — | — |
| 2026-09-15 | David W. Boyer | Chief Corp. Affairs Officer | MIXED | — | — |
| 2026-09-15 | KEVIN CHARLES GORMAN | Director | MIXED | — | — |
| 2026-09-15 | Sanjay Chandru Keswani | Chief Medical Officer | MIXED | — | — |
| 2026-09-15 | Julie Cooke | Chief Human Resources Officer | MIXED | — | — |
| 2026-09-15 | ERIC BENEVICH | Chief Commercial Officer | MIXED | — | — |
| 2026-09-15 | Ingrid Delaet | Chief Regulatory Officer | MIXED | — | — |
| 2026-09-15 | Kyle Gano | Chief Executive Officer | MIXED | — | — |
| 2026-09-15 | Jude Onyia | Chief Scientific Officer | MIXED | — | — |
| 2026-09-10 | ERIC BENEVICH | Chief Commercial Officer | MIXED | — | — |
| 2026-09-03 | STEPHEN A SHERWIN | Director | G | — | — |
| 2026-08-05 | Jude Onyia | Chief Scientific Officer | G | — | — |
| 2026-07-30 | Leslie V Norwalk | Director | MIXED | — | — |
| 2026-07-13 | Ingrid Delaet | Chief Regulatory Officer | MIXED | — | — |
| 2026-07-13 | Darin Lippoldt | Chief Legal Officer | MIXED | — | — |
| 2026-07-09 | Ingrid Delaet | Chief Regulatory Officer | MIXED | — | — |
| 2026-06-09 | Jude Onyia | Chief Scientific Officer | G | — | — |
| 2026-06-09 | STEPHEN A SHERWIN | Director | MIXED | — | — |
| 2026-06-08 | Leslie V Norwalk | Director | Sell | — | — |
| 2026-06-04 | Sanjay Chandru Keswani | Chief Medical Officer | MIXED | — | — |
| 2026-06-04 | Julie Cooke | Chief Human Resources Officer | MIXED | — | — |
| 2026-06-02 | Ingrid Delaet | Chief Regulatory Officer | MIXED | — | — |
| 2026-06-02 | Jude Onyia | Chief Scientific Officer | MIXED | — | — |
| 2026-05-29 | Leslie V Norwalk | Director | A | — | — |
| 2026-05-29 | WILLIAM H RASTETTER | Director | A | — | — |
| 2026-05-29 | GEORGE J MORROW | Director | A | — | — |
| 2026-05-29 | STEPHEN A SHERWIN | Director | A | — | — |
| 2026-05-29 | Shalini Sharp | Director | A | — | — |
| 2026-05-29 | CHRISTINE A POON | Director | A | — | — |
| 2026-05-29 | Johanna Mercier | Director | A | — | — |
| 2026-05-29 | GARY A LYONS | Director | A | — | — |
| 2026-05-29 | RICHARD F POPS | Director | A | — | — |
| 2026-05-29 | KEVIN CHARLES GORMAN | Director | A | — | — |
| 2026-05-29 | Jude Onyia | Chief Scientific Officer | MIXED | — | — |
| 2026-05-28 | David W. Boyer | Chief Corp. Affairs Officer | Sell | — | — |
| 2026-05-21 | KEVIN CHARLES GORMAN | Director | MIXED | — | — |
| 2026-05-21 | GARY A LYONS | Director | M | — | — |
| 2026-05-21 | Johanna Mercier | Director | M | — | — |
| 2026-05-21 | GEORGE J MORROW | Director | M | — | — |
| 2026-05-21 | Leslie V Norwalk | Director | M | — | — |
| 2026-05-21 | CHRISTINE A POON | Director | M | — | — |
| 2026-05-21 | RICHARD F POPS | Director | M | — | — |
| 2026-05-21 | WILLIAM H RASTETTER | Director | M | — | — |
| 2026-05-21 | Shalini Sharp | Director | M | — | — |
| 2026-05-21 | STEPHEN A SHERWIN | Director | M | — | — |
| 2026-05-18 | RICHARD F POPS | Director | MIXED | — | — |
| 2026-05-14 | Leslie V Norwalk | Director | Sell | — | — |
| 2026-03-05 | MATT ABERNETHY | Chief Financial Officer | G | — | — |
| 2026-02-23 | Jude Onyia | Chief Scientific Officer | G | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | — | 10,257,894 | — |
| — | 10%+ Owner | 8,847,147 | — |
| — | 10%+ Owner | 6,658,212 | — |
| — | — | 5,905,447 | — |
| — | — | 756,600 | — |
| — | Director | 517,797 | — |
| — | Chief Development Officer | 157,651 | — |
| — | Chief Executive Officer | 153,880 | — |
| — | Chief Financial Officer | 137,961 | — |
| — | Director | 122,141 | — |
| — | EVP and General Counsel | 118,256 | — |
| — | Chief Research Officer | 82,273 | — |
| — | Chief Commercial Officer | 70,683 | — |
| — | Chief Legal Officer | 59,212 | — |
| — | Director | 56,042 | — |
| — | Former Chief Medical Officer | 55,946 | — |
| — | Chief Financial Officer | 47,828 | — |
| — | Director | 43,678 | — |
| — | Director | 43,283 | — |
| — | Chief Integration Officer | 42,337 | — |
| — | Director | 37,798 | — |
| — | Chief Medical Officer | 34,252 | — |
| — | Chief Human Resources Officer | 24,025 | — |
| — | Chief Scientific Officer | 22,647 | — |
| — | Chief Regulatory Officer | 18,289 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NBIX quote page; the site-wide leaderboard is on the insider transactions hub.